Results 111 to 117 of about 584 (117)

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human

Vaccine, 2014
Soren Tetens Hoff, Morten Ruhwald, Peter Andersen   +2 more
exaly  

CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations

International Journal of Pharmaceutics, 2010
Peter Andersen, Hanne Mørck Nielsen, Ida Rosenkrands   +2 more
exaly  

Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01

Vaccine, 2011
Peter Bang, Peter Andersen, Íngrid Kromann   +2 more
exaly  

Design of Gadoteridol-Loaded Cationic Liposomal Adjuvant CAF01 for MRI of Lung Deposition of Intrapulmonary Administered Particles

Molecular Pharmaceutics, 2019
Bjørn Quistorff, Samuel Maritim, Yuki Mori   +2 more
exaly  

Lipid conjugation of TLR7 agonist Resiquimod ensures co-delivery with the liposomal Cationic Adjuvant Formulation 01 (CAF01) but does not enhance immunopotentiation compared to non-conjugated Resiquimod+CAF01

Journal of Controlled Release, 2018
Gabriel Pedersen, Yvonne Perrie, Eric Lattmann   +2 more
exaly  

Vaccination with a Hybrid 1 (H1) fusion protein combined with a liposomal adjuvant (CAF01) induced antigen specific T-cells 3 years post vaccination in a human clinical trial. (VAC7P.971)

Journal of Immunology, 2014
Andersen Peter
exaly  

A CAF01-adjuvanted whole asexual blood-stage liposomal malaria vaccine induces a CD4 + T-cell-dependent strain-transcending protective immunity in rodent models

MBio
Michael Good, Danielle Stanisic, Winter Okoth   +2 more
exaly